Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This rapid response report from the Canadian Agency for Drugs and Technologies in Health (CADTH) reviews the clinical effectiveness of botulinum toxin A for reduction in pain and improvement of functioning in patients with migraine headache
 
It found that, 'the evidence is inconclusive regarding the clinical effectiveness of botulinum toxin A for reduction in pain and improvement of functioning in patients with migraine headache'.
 
The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sou...

More...